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OBJECTIVE—Left ventricular hypertrophy (LVH), an independent risk factor for cardio-
vascular (CV) morbidity and mortality, recognizes a multifactorial pathogenesis. A plasma
glucose value $155 mg/dL for the 1-h postload plasma glucose during an oral glucose toler-
ance test (OGTT) identiﬁes subjects with normal glucose tolerance (NGT) at high risk for
type 2 diabetes. We addressed the question if glucose tolerance status, particularly 1-h postload
plasma glucose levels, affects left ventricular mass (LVM) and cardiac geometry in essential
hypertension.
RESEARCH DESIGN AND METHODS—We enrolled 767 never-treated hypertensive
subjects, 393 women and 374 men (mean age 49.6 6 8.5 years). All patients underwent an
OGTT for the evaluation of glucose tolerance and standard echocardiography. LVM was calcu-
lated using the Devereux formula and normalized by body surface area (LVM index [LVMI]).
InsulinsensitivitywasassessedbytheMatsudaindex.Amongallparticipants,514hadNGT,168
hadimpairedglucosetolerance(IGT), and 85 hadtype 2diabetes.Accordingto the1-h postload
plasma glucose cutoff point of 155 mg/dL, we divided normotolerant subjects into two groups:
NGT ,155 mg/dL (n = 356) and NGT $155 mg/dL (n = 158).
RESULTS—Subjects in the NGT $155 mg/dL group had worse insulin sensitivity than sub-
jects in the NGT ,155 mg/dL group (Matsuda index 63.9 vs. 88.8; P, 0.0001). Men with NGT
$155 mg/dL had a higher LVMI than men with NGT ,155 mg/dL (126.6 vs. 114.3 g/m
2; P =
0.002) and a different LVH prevalence (41.1 vs. 25.8%; P , 0.0001). At multiple regression
analysis, 1-h glucose resulted in the major determinant of LVMI in normotolerant, IGT, and
diabetic groups.
CONCLUSIONS—These data show that NGT $155 mg/dL subjects, compared with NGT
,155mg/dL subjects,have a higher LVMI and a greater prevalence of LVH similar to thatof IGT
and diabetic patients.
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L
eft ventricular hypertrophy (LVH)
represents an independent risk fac-
tor for cardiovascular (CV) morbid-
ityandmortalityinessentialhypertension
(1) and in the general population (2). Left
ventricular mass (LVM) increase is not
only the consequence of adaptative car-
diac remodeling to pressure overload,
but it recognizes a complex and multifac-
torialpathogenesis.Infact,severalstudies
have demonstrated that hypertension ex-
plains only a 10–25% variation of LVM,
conﬁrmingthehypothesisthatothernon-
hemodynamic factors such as salt reten-
tion (3) and genetic (4), hormonal, and
metabolic factors (5) are involved in the
LVM increase.
It is known that type 2 diabetes is an
independent risk factor for heart failure
independently of coronary artery disease
or hypertension (6). A possible explana-
tion is that the metabolic abnormalities
characterizing type 2 diabetes may affect
the cardiac structure, promoting the LVH
appearance (7,8). In addition, subjects
with impaired glucose tolerance (IGT)
and/or impaired fasting glucose (IFG)
are characterized by an unfavorable CV
risk proﬁle (9). Rutter et al. (7) demon-
strated that glucose metabolism worsen-
ing, tested by an oral glucose tolerance
test (OGTT), is more strongly associated
with LVH in women than in men. Simi-
l arl y,w omeni ntheHo ornstud ys how ed
eccentricorconcentricLVHaccordingto
IGT (8).
Recently, a cutoff point of 155 mg/dL
for the 1-h postload plasma glucose dur-
ing an OGTT identiﬁes subjects with
normal glucose tolerance (NGT) at high
risk for type 2 diabetes (10). Moreover, a
1-h postload plasma glucose value is
strongly associated with carotid intima-
media thickness (IMT) (11), a subclinical
organdamageandanindependentpredic-
tor for CV events (12).
Taken together, we designed this
study to address the question if glucose
tolerancestatus,andinparticular1-hpost-
loadplasmaglucoselevels,mayaffectLVM





We enrolled 767 Caucasian hypertensive
outpatients who were free of complica-
tions (393 men and 374 women aged 40–
70 years [mean 6 SD 49.6 6 8.5]) and
participating in the Catanzaro Metabolic
Risk Factors Study (CATAMERIS). Causes
of secondary hypertension were excluded
by appropriate clinical and biochemical
tests. Other exclusioncriteriawerehistory
or clinical evidence of coronary and val-
vular heart disease, congestive heart fail-
ure, hyperlipidemia, peripheral vascular
disease, chronic gastrointestinal disease
associated with malabsorption, chronic
pancreatitis,historyofanymalignantdis-
ease, history of alcohol or drug abuse, liver
or kidney failure, and treatment to modify
glucose metabolism. No patient had ever
been treated with antihypertensive drugs.
All subjects underwent anthropometrical
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After a 12-h fast, a 75-g OGTT was
performed with 0, 30, 60, 90, and 120
min sampling for plasma glucose and
insulin. Glucose tolerance status was de-
ﬁned on the basis of OGTT using the
World Health Organization criteria. In-
sulin sensitivity was evaluated using the
Matsuda index (insulin sensitivity index
[ISI]) calculated as follows: 10,000/square
root of [fasting glucose (millimoles per
liter) 3 fasting insulin (milliunits per
liter)]3[meanglucose3meaninsulindur-
ing OGTT]. The Matsuda index is strongly
related to the euglycemic-hyperinsulinemic
clamp, which represents the gold standard
test for measuring insulin sensitivity (13).
An ethics committee approved the proto-
col, and informed written consent was
obtained from all participants. All inves-
tigations were performed in accordance
with the principles of the Declaration of
Helsinki.
Blood pressure measurements
Clinic blood pressure readings were ob-
tained from the left arm of supine pa-
tients, after 5 min of quiet rest, with a
mercury sphygmomanometer. A mini-
mum of three blood pressure readings
were taken on three separate occasions at
least 2 weeks apart. Baseline blood pres-
sure values were the average of the last
two of three consecutive measurements
obtained at intervals of 3 min. Patients
with a clinic systolic blood pressure (SBP)
.140mmHgand/ordiastolicbloodpres-
sure (DBP) .90 mmHg were deﬁned as
hypertensive.
Laboratory determinations
Plasma glucose was measured by the
glucoseoxidationmethod(BeckmanGlu-
cose Analyzer II; Beckman Instruments,
Milan, Italy). Triglyceride and total and
HDL cholesterol concentrations were
measured by enzymatic methods (Roche
Diagnostics, Mannheim, Germany). Plasma




Tracings were taken with patients in a
partial left decubitus position using a
VIVID-7 Pro ultrasound machine (GE
Technologies, Milwaukee, WI) with an
annular phased array 2.5-MHz trans-
ducer. Echocardiographic readings were
made in random order by the investiga-
tor, who had no knowledge of patients’
blood pressure and other clinical data.
Only frames with optimal visualization
of cardiac structures were considered for
reading. The mean values from at least
ﬁve measurements of each parameter for
each patient were computed. Having the
same experienced sonographer perform
all studies in a dimly lit and quiet room
optimizedthereproducibilityofmeasure-
ments. In our laboratory, the intraob-
server coefﬁcients of variation (CVs)
were3.85%forposteriorwall(PW)thick-
ness, 3.70% for interventricular septal
(IVS) thickness, 1.50% for left ventricular
internal diameter (LVID), and 5.10% for
LVM.
M-mode measurements
Tracings were recorded under two-
dimensionalguidance,andM-modemea-
surements were taken at the tip of the
mitral valve or just below. Measurements
ofIVSthickness,PWthickness,andLVID
were made at end-diastole and end-
systole. LVM was calculated using the De-
vereux equation (14) and normalized by
body surface area (LVM index [LVMI]).
Partition values for LVH were taken with
the cutoff value of 125 g/m
2 for both
women and men, as suggested by Casale
et al. (15).
Patterns of left ventricular geometry
Relative wall thickness (RWT) was mea-
sured at end-diastole as the ratio of the
(IVS + PW)/LVID. A value of 0.45 was
considered to be the cutoff for normal.
Concentric remodeling or concentric
LVH was deﬁn e db ya nR W T.0.45.
Statistical analysis
ANOVA for clinical and biological data
was performed to test the differences
among groups, and the Bonferroni post
hoc test for multiple comparisons was
further performed. The x
2 test was used
for categorical variables. Correlation co-
efﬁcients were calculated according to
Pearson’smethod.Linearregressionanal-
ysis was performed to relate LVMI to the
following covariates: age, BMI, WC, SBP,
DBP, fasting, 1-h and 2-h postload plasma
glucose levels, fasting insulin, Matsuda
index,andhigh-sensitivityC-reactivepro-
tein (hs-CRP). Subsequently, variables
reaching statistical signiﬁcance and sex,
as a dicotomic value, were inserted in a
stepwise multivariate linear regression
model to determine the independent
predictors of LVMI. Correlation analysis
was performed for the whole study pop-
ulationandaccordingtodifferentgroups
of glucose tolerance. Data are reported as
means 6 SD. Differences were assumed
to be signiﬁcant at P , 0.05. All compar-
isonswereperformedusingthestatistical




Of 767 patients examined by OGTT, 514
hadNGT,168hadIGT,and85hadnewly
diagnosedtype2 diabetes.A1-hpostload
plasma glucose cutoff point of 155 mg/dL
duringanOGTTwasusedtostratifyNGT
subjects into two groups: 356 patients
with 1-h postload plasma glucose ,155
mg/dL (NGT ,155) and 158 individuals
with 1-h postload plasma glucose $155
mg/dL (NGT $155). Table 1 shows the
demographic, clinical, and biochemical
characteristics of the four study groups.
There was a signiﬁcant difference in
sex distribution among the groups (P =
0.031); in particular, in type 2 diabetic
patients and in NGT $155, there was a
major prevalence of men (63.5 and
54.4%, respectively). In the IGT group,
w o m e nw e r em o r ep r e v a l e n tt h a nm e n
(55.9 vs. 44.0%). On the contrary, there
was no signiﬁcant difference among
groups for BMI, DBP, and total and HDL
cholesterol. From the ﬁrst to the fourth
group, there was a signiﬁcant increase
in WC (P =0 . 0 0 8 ) ,S B P( P , 0.0001),
triglycerides (P = 0.001), and in hs-CRP
values (P , 0.0001). Obviously, a pro-
gressive increase of fasting, 1-h and 2-h
postload glucose, as well as fasting and
2-h insulin, parallel the worsening of glu-
cose tolerance (P , 0.0001), explaining
the reduction of Matsuda index/ISI.
Moreover, NGT $155 had signiﬁcantly
reduced insulin sensitivity (P , 0.0001)
and increased hs-CRP values (P = 0.001)
whencomparedwithNGT,155andhad
metabolic and inﬂammatory proﬁles sim-
ilar to IGT individuals.
Echocardiographic parameters and
glucose tolerance
Echocardiographic parameters for the
study population and for women and
men, according to glucose tolerance
groups, are reported in Table 2. Consid-
ering the whole study cohort, the type 2
diabetic patients had the highest end-
diastolic LVID (EDLVID) (P =0 . 0 1 8 )a n d
diastolic PW (dPW) (P = 0.008) values,
but there were no signiﬁcant differences
for IVS among groups. Moreover, LVMI
care.diabetesjournals.org DIABETES CARE, VOLUME 34, JUNE 2011 1407
Sciacqua and Associatesvaluessigniﬁcantlyincreasedfromtheﬁrst
to the fourth group (P = 0.002). Notably,
NGT $155 subjects showed an LVMI
value not signiﬁcantly different from IGT
(P = 0.999) and type 2 diabetic patients
(P = 0.999) but signiﬁcantly higher com-
p a r e dw i t hN G T,155 subjects. Also,
RWT was signiﬁcantly different among
the study groups (P =0 . 0 1 3 ) .
The prevalence of LVH signiﬁcantly
increased fromtheﬁrst tothe fourth group
(P =0 . 0 0 1 )a n dN G T$155 subjects
showed an LVH prevalence signiﬁ-
cantly higher than NGT ,155 subjects
(P , 0.0001) and similar to that of IGT
(P = 0.435) and type 2 diabetic patients (P =
0.896). No signiﬁcant differences among
groups were observed for the LVH pattern
(P =0 . 9 9 9 ) .
In women, EDLVID, diastolic IVS
(dIVS), dPW, and LVMI were not signif-
icantly different among groups, whereas
RWT was signiﬁcantly higher in IGT and
type 2 diabetic patients (P = 0.018). The
LVHprevalencewas27.7%inNGT,155
subjects, 36.1% in NGT $155 subjects,
34% in IGT, and 41.9% in type 2 diabetic
patients; this distribution was not signiﬁ-
cantly different (P = 0.406).
In men, with worsening glucose tol-
erance, EDLVID (P =0 . 0 1 0 )a n dL V M I
signiﬁcantly increased (P = 0.001). There
was no signiﬁcant difference for dIVS and
dPWamonggroups.Notably,NGT$155
subjects showed an LVMI value signiﬁ-
cantly higher than NGT ,155 subjects
(P = 0.044), but not signiﬁcantly different
from IGT and type 2 diabetic patients.
LVH prevalence was 24% in NGT ,155
subjects, 45.3% in NGT $155 subjects,
3 9 . 2 %i nI G T ,a n d4 0 . 7 %i nt y p e2d i a -
betic patients, with a signiﬁcantly differ-
ent distribution among groups (P ,
0.0001). NGT $155 subjects showed an
LVHprevalencesimilartoIGT(P=0.532)
and type 2 diabetic (P = 0.719) patients
but showed a signiﬁcantly higher preva-
lence than NGT ,155 subjects (P ,
0.0001). Finally, no signiﬁcant differences
among groups were observed for the LVH
pattern (P =0 . 8 9 1 ) .
Table 1—Anthropometric, hemodynamic, and biochemical characteristics of the study population according to glucose tolerance
NGT ,155 NGT $155 IGT Type 2 diabetes P
n 356 158 168 85 —
Sex (M/F) 179/177 86/72 74/94 54/31 0.031*
Age (years) 48.6 6 9.6 50.9 6 7.9 49.7 6 6.2 49.7 6 6.2 0.030
BMI (kg/m
2) 29.9 6 5.6 31.1 6 6.1 31.1 6 5.3 31.1 6 5.4 0.065
WC (cm) 101.2 6 13.5 103.5 6 12.9 104.3 6 12.8 106.1 6 12,5 0.008
SBP (mmHg) 137.1 6 15.8 139.4 6 16.3 143.6 6 17.7 143.6 6 19.5 ,0.0001
DBP (mmHg) 84.7 6 10.8 84.5 6 10.2 85.7 6 10.4 86.2 6 11.5 0.473
Fasting glucose (mg/dL) 91.5 6 10.3 94.7 6 11.1 98.1 6 13.1 120.7 6 33.8 ,0.0001
1-hour glucose (mg/dL) 120.2 6 22.4 184.4 6 27.5 188.7 6 34.3 245.8 6 45.8 ,0.0001
2-hour glucose (mg/dL) 101.2 6 19.7 114.3 6 17.5 162.1 6 16.2 242.1 6 46.1 ,0.0001
Fasting insulin (mU/mL) 11.3 6 6.2 12.7 6 6.9 15.5 6 9.8 15.9 6 10.1 ,0.0001
1-hour insulin (mU/mL) 94.5 6 63.6 105.2 6 61.4 100.8 6 49.8 88.1 6 56.1 0.103
2-hour insulin (mU/mL) 64.1 6 49.4 76.2 6 52.6 128.5 6 76.9 110.1 6 65.2 ,0.0001
Matsuda index/ISI 88.8 6 61.9 63.9 6 50.3 48.8 6 32.5 41.8 6 29.2 ,0.0001
Total cholesterol (mg/dL) 203.5 6 40.8 201.1 6 34.7 206.5 6 41.1 205.3 6 46.8 0.641
HDL cholesterol (mg/dL) 51.8 6 14.5 50.8 6 13.2 50.2 6 13.1 49.6 6 15.1 0.430
Triglycerides (mg/dL) 127.9 6 70.4 125.6 6 66.1 147.1 6 77.1 155.4 6 84.3 0.001
hs-CRP (mg/L) 2.1 6 1.2 2.7 6 1.4 2.9 6 1.7 3.7 6 1.9 ,0.0001
*x
2 Test.
Table 2—Echocardiographic parameters according to glucose tolerance in the whole
study population and according to sex
NGT ,155 NGT $155 IGT Type 2 diabetes P
n 356 158 168 85 —
EDLVID (cm) 4.89 6 0.40 4.93 6 0.39 4.87 6 0.43 5.03 6 0.36 0.018
dIVS (cm) 1.07 6 0.18 1.10 6 0.18 1.10 6 0.18 1.11 6 0.14 0.065
dPW (cm) 0.97 6 0.18 0.98 6 0.18 1.02 6 0.18 1.02 6 0.14 0.008
LVMI (g/m
2)1 1 4 . 8 6 32.6 122.4 6 39.1 122.8 6 33.3 127.9 6 27.9 0.002
RWT 0.42 6 0.07 0.43 6 0.07 0.44 6 0.07 0.42 6 0.05 0.013
LVH [n (%)] 92 (25.8) 65 (41.1) 61 (36.3) 35 (41.1) 0.001
Women
n 177 72 94 31 —
EDLVID (cm) 4.82 6 0.39 4.87 6 0.39 4.76 6 0.42 4.81 6 0.44 0.397
dIVS (cm) 1.05 6 0.18 1.07 6 0.16 1.09 6 0.19 1.10 6 0.15 0.225
dPW (cm) 0.95 6 0.20 0.93 6 0.13 0.97 6 0.15 0.96 6 0.17 0.059
LVMI (g/m
2)1 1 5 . 4 6 33.1 117.4 6 32.8 120.2 6 33.5 119.7 6 25.4 0.673
RWT 0.42 6 0.08 0.41 6 0.05 0.44 6 0.07 0.44 6 0.07 0.018
LVH [n (%)] 49 (27.7) 26 (36.1) 32 (34.0) 13 (41.9) 0.406
Men
n 179 86 74 54 —
EDLVID (cm) 4.96 6 0.40 4.97 6 0.39 5.01 6 0.39 5.16 6 0.22 0.010
dIVS (cm) 1.09 6 0.18 1.13 6 0.19 1.11 6 0.17 1.12 6 0.14 0.326
dPW (cm) 0.99 6 0.16 1.03 6 0.21 1.06 6 0.21 1.04 6 0.14 0.027
LVMI (g/m
2)1 1 4 . 3 6 32.1 126.6 6 43.5 126.1 6 32.9 132.6 6 28.5 0.001
RWT 0.42 6 0.07 0.44 6 0.08 0.44 6 0.06 0.42 6 0.04 0.071
LVH [n (%)] 43 (24.0) 39 (45.3) 29 (39.2) 22 (40.7) 0.002
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A linear regression analysis was per-
formed to test the correlation between
LVMI and different covariates (Table 3).
In the whole study population, LVMI was
signiﬁcantly correlated with age (P =
0.002), BMI (P , 0.0001), WC (P ,
0.0001), SBP (P = 0.014), 1-h and 2-h
postloadglucose(P,0.0001),fastingin-
sulin (P , 0.0001), Matsuda index/ISI
(P , 0.0001), and hs-CRP (P , 0.0001).
In NGT ,155 subjects, LVMI was signif-
icantly correlated with age (P =0 . 0 1 1 ) ,
BMI (P , 0.0001), WC (P , 0.0001),
1-h postload glucose (P = 0.006), fasting
insulin (P = 0.028), Matsuda index/ISI
(P = 0.037), and hs-CRP (P = 0.002). In
NGT $155 subjects, LVMI correlated
with BMI (P = 0.005), WC (P = 0.004),
1-h postload glucose (P , 0.0001), and
insulin (fasting, P = 0.034; 1-h postload,
P = 0.015; 2-h postload, P = 0.004). In
IGT patients, LVMI was correlated with
1-hpostloadglucose(P,0.0001),fasting
insulin (P = 0.002), Matsuda index/ISI
(P = 0.007), and hs-CRP (P , 0.0001).
Finally,indiabeticpatients,LVMIwassta-
tistically correlated with BMI (P ,
0.0001), WC (P =0 . 0 0 2 ) ,1 - h( P , 0.0001)
and 2-h postload glucose (P , 0.0001),
fasting (P , 0.0001) and 1-h postload
insulin (P = 0.012), and hs-CRP (P ,
0.0001).
Thus, variables reaching statistical
signiﬁcance and sex, as a dichotomic
value, were inserted in a stepwise multi-
variate linear regression model to deter-
minethe independentpredictorsofLVMI
variation (Table 4). In the whole popula-
tion, 1-h postload glucose was the major
predictor of LVMI, explaining 8.9% of its
variation (P , 0.0001). Other indepen-
dent predictors were WC, fasting insulin,
hs-CRP, 2-h postload glucose, age, and
sex, explaining 18.7% of the LVMI varia-
tion. In NGT ,155 subjects, the main
predictor of LVMI was waist, accounting
for 4.0% of its variation (P , 0.0001);hs-
CRP, age, and fasting insulin explained a
further 7.0% of its variation. In NGT
$155 subjects, IGT, and type 2 diabetic
patients, 1-h postload glucose was the
strongest predictor of LVMI, accounting
for 27.9% (P , 0.0001), 15% (P ,
0.0001), and 25.1% (P , 0.0001) of its
v a r i a t i o ni nt h er e s p e c t i v em o d e l s .I n
NGT $155 subjects, 1-h postload insulin
and SBP were retained as independent
predictors of LVMI, explaining another
4.5% of its variation. In IGT patients,
hs-CRP, sex, and fasting insulin were en-
tered in the analysis, and the ﬁnal model
accounted for 27.5% of LVMI variation.
In type 2 diabetic patients, BMI, fasting
insulin hs-CRP, and sex were also signif-
icantly included in the ﬁnal model, ac-
counting for a further 19.3% (P , 0.0001),
9.3% (P , 0.0001), 4.9% (P = 0.005),
and 2.3% (P = 0.049), respectively. The
entire model explained 53.9% of LVMI
variation.
CONCLUSIONS—This study, con-
ducted in a large cohort of untreated
hypertensive subjects, showed that wors-
ening glucose tolerance was associated
with an LVM increase in the whole study
population and men, but not in women.
Clinically relevant, NGT $155 subjects
had LVMI values signiﬁcantly higher
than NGT ,155 subjects and similar to
IGT and type 2 diabetic patients. This
condition was particularly evident in
men. Obviously, as expected, LVMI was
signiﬁcantly greater in men than in
women.
Similarly, the prevalence of LVH,
which is an important predictor of CV
events, increased consistently from NGT
,155 subjects to type 2 diabetic patients.
It is important to remark that NGT $155
subjects have, in the whole population,
the same LVH prevalence of type 2 dia-
betic patients; whereas in men, it is even
greater (45.3 vs. 40.7%). In addition,
stepwise multiple regression analysis re-
tained 1-h postload plasma glucose as the
ﬁrst independent predictor of LVM in all
groups (Table 4). In particular, it explains
the 27.9% of LVM variation in NGT
$155 subjects, 25.1% in type 2 diabetic
patients,15%intheIGTgroup,and8.9%
in the whole study population.
Our results are in agreement with
other previously published data, al-
though these studies have not investi-
gated the association between postload
plasma glucose and cardiac mass. In
particular, women enrolled in both the
Framingham (7) and Hoorn (8) studies
showed, with worsening of glucose
tolerance, a progressive increase of LVM
values. In addition, Verdecchia et al. (16)
reported, in ﬁrst-diagnosis hypertensive
NGT patients, the 2-h postload insulin,
but not plasma glucose, as the main de-
terminant of LVM. This discordance is
due, at least in part, to the different cate-
gorization of NGT subjects, divided by us
into two groups on the basis of 1-h
Table 3—Univariate linear regression analysis between LVMI and different covariates, in the whole study population and in groups
with different glucose tolerance
All NGT ,155 NGT $155 IGT Type 2 diabetes
RPRPRPRPRP
One-hour glucose (mg/dL) 0.299 ,0.0001 0.134 0.006 0.528 ,0.0001 0.387 ,0.0001 0.501 ,0.0001
hs-CRP (mg/L) 0.214 ,0.0001 0.152 0.002 20.041 0.302 0.329 ,0.0001 0.368 ,0.0001
Fasting insulin (mU/mL) 0.199 ,0.0001 0.101 0.028 0.145 0.034 0.222 0.002 0.408 ,0.0001
BMI (kg/m
2)0 . 1 7 7 ,0.0001 0.182 ,0.0001 0.204 0.005 0.083 0.144 0.460 ,0.0001
WC (cm) 0.169 ,0.0001 0.201 ,0.0001 0.210 0.004 0.089 0.125 0.317 0.002
Two-hour glucose (mg/dL) 0.147 ,0.0001 20.033 0.267 0.131 0.051 0.006 0.471 0.452 ,0.0001
Age (years) 0.105 0.002 0.122 0.011 0.038 0.318 0.109 0.079 0.081 0.231
SBP (mmHg) 0.079 0.014 0.076 0.077 0.117 0.072 20.029 0.352 0.068 0.267
Fasting glucose (mg/dL) 0.046 0.103 20.011 0.417 0.074 0.178 20.038 0.311 20.066 0.274
DBP (mmHg) 20.030 0.204 20.057 0.140 20.010 0.449 20.017 0.411 20.044 0.346
Matsuda index/ISI 20.143 ,0.0001 20.095 0.037 20.103 0.099 20.187 0.007 20.193 0.039
One-hour insulin (mU/mL) 0.058 0.054 0.011 0.415 0.173 0.015 0.011 0.445 0.245 0.012
Two-hour insulin (mU/mL) 0.034 0.171 0.016 0.380 0.213 0.004 0.054 0.242 0.175 0.055
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Verdecchia et al. (16), in the NGT $155
group, postload insulin was retained in
the multivariable analysis as an indepen-
dent predictor of LVMI; notably, the im-
pactofpostloadinsulininourpopulation
was less than for postload glucose. These
ﬁndings emphasize the role of 1-h meta-
bolic modiﬁcations in early identiﬁcation
of subjects at high risk.
Another important ﬁnding is that
NGT $155 subjects have both hs-CRP
and insulin resistance (IR) levels similar
to IGT that are considered at high risk
for both type 2 diabetes and CV disease
(17). The coexistence of an increased
LVM contributes to further amplify their
CV risk proﬁle. In addition, our data con-
sent to reconsider the concept that NGT
subjects are a homogeneous group with a
low CV risk. Nevertheless, the evidence
that NGT $155 subjects have cardiac
modiﬁcationssimilartoIGTsubjectscon-
ﬁrms that the major pathogenetic mecha-
nism promoting organ damage is IR.
Finally, the present results are in agree-
ment with previously published data
demonstrating that subclinical inﬂamma-
tion participates in IR development and
its progression to type 2 diabetes.
The direct effectofplasma glucose and
its associated abnormalities, as the proin-
ﬂammatory state and IR/hyperinsulinemia,
may explain the increase of LVM (5). It is
well known that chronic hyperglycemia
promotestheformationofadvancedglyca-
tion end products (AGEs) and, through
protein kinase C activation, to reactive ox-
ygen species production (18). AGEs make
irreversibleandstablelinkswithcollagen
polymers, leading to ﬁbrosis develop-
ment, as observed in animal models (19).
Moreover, under chronic hyperglycemia,
there is an increased turnover of free fatty
acids, with a shift of myocardial metabo-
lism toward the oxidation of the latter
(20). Our results clearly indicate that these
modiﬁcations begin early, at a clinically
silent phase.
In addition, IR/hyperinsulinemia in-
creases LVM by the insulin binding to its
receptors and to IGF-I receptors, ex-
pressed in the myocardium (21). IGF-I
stimulates hypertrophy and differentia-
tion of cardiomyocytes, as demonstrated
in in vivo and in vitro studies (21,22).
Moreover, hyperinsulinemia may cause
renal sodium retention, affecting cardiac
preload, which is another factor involved
in LVM increase (23). The activation of
both the renin-angiotensin-aldosterone
system and sympathetic nervous system
are other important mechanisms poten-
tially involved in cardiac mass increase
promoting oxidative stress, stimulating
cardiac ﬁbroblast, and increasing heart
rate and cardiac overload (24).
In conclusion, the most clinically
relevant information from this study is
that there is a statistically signiﬁcant and
direct correlation between 1-h postload
plasma glucose and LVM in hypertensive
patients. Particularly, in men but not in
women, NGT $155 subjects showed an
LVH prevalence signiﬁcantly higher than
NGT ,155 subjects and similar to IGT
and type 2 diabetic patients. Our data
have allowed us to identify a new early
predictoroforgandamageandemphasize
theimportancetoperformanOGTTinall
hypertensive subjects, paying attention
n o to n l yt o2 - hb u ta l s ot o1 - hp o s t l o a d
plasma glucose values, which are more
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